BioBridgeX
Log inCompare quotes
CMC / Manufacturing

Cell Line / Strain Development CDMOs

Free for buyersNeutral marketplace
Quick answer

Cell line or strain development is the work of building and banking the engineered host (CHO, HEK293, yeast, or bacteria) that expresses your drug, then characterizing it for stability and productivity. You need it once a lead biologic is chosen, before process development and GMP supply. BioBridgeX lets buyers source and compare qualified CDMOs.

Cell Line / Strain Development CDMOs on BioBridgeX

We are qualifying and publishing Cell Line / Strain Development CDMOs now. Tell us what you need and we will match you with vetted vendors, or list your organization to be among the first.

What is cell line / strain development and when do you need it?

Cell line development is how you turn a chosen biologic sequence into a stable, productive, manufacturable cell or strain. For most antibodies and recombinant proteins that means a CHO host; for some proteins and viral vectors it is HEK293; for simpler molecules, peptides, and many enzymes it is a microbial strain such as E. coli or Pichia (the yeast side of the work is usually called strain development rather than cell line development, but buyers shop for both under the same heading). The deliverable is not just a flask of cells. It is a documented, clonal, banked, and characterized production system with a known titer and a stability story you can defend to a regulator.

The work sits at a specific point in the timeline. You commission it once molecule discovery has converged on a lead and you are committing to make real material: tox supplies, then GMP drug substance for the clinic. It comes before, and feeds directly into, upstream and downstream process development. Get the cell line wrong and every downstream cost compounds, because you are optimizing a process around a clone that may underproduce or drift. That is why teams treat clone selection as a gating decision, not a formality.

A typical program runs in the range of three to six months from gene to a research cell bank, longer if you need a GMP master cell bank with full characterization and adventitious agent testing. The main levers a buyer actually decides on are the expression platform (which often comes with licensing terms attached), the host and vector, the productivity target in grams per liter, and how much clonality documentation and stability data you want before you lock the clone. Those choices shape your timeline, your royalty exposure, and how smoothly your eventual BLA reads.

What does a cell line / strain development CDMO actually do?

The provider takes your sequence (or your existing pool) and runs it through transfection or transformation, selection, and clone screening, usually narrowing thousands of candidates down to a short list using single-cell cloning and imaging to support a clonality claim. They run fed-batch or shake-flask assessments to rank clones on titer, growth, and product quality, then characterize the lead on the attributes that matter for your molecule: charge variants, glycosylation, aggregation, and sequence integrity.

From there the scope usually extends into banking and qualification. A good CDMO will generate a research cell bank, then a GMP master cell bank (MCB) and working cell bank (WCB), and run the genetic stability and adventitious agent testing that supports limit-of-in-vitro-cell-age (LIVCA) claims. Many also offer the natural next steps under one roof: upstream and downstream process development, analytical method development, and GMP drug substance manufacturing. Whether you want that continuity, or prefer to develop the line at one shop and manufacture at another, is a real decision with tech-transfer consequences, and it is worth deciding up front rather than discovering the seams later.

How to choose a cell line / strain development CDMO?

The right partner depends on your molecule, your timeline, and how far you intend to carry the program with one supplier. A microbial strain for a simple protein and a high-titer CHO line headed for commercial supply are different briefs, and the strongest provider for one is rarely the strongest for the other. Use the checklist below to compare candidates on the things that actually move risk and cost, then talk to two or three before you commit.

  • Quality and GxP status: confirm GMP banking capability, a clonality strategy that will satisfy FDA and EMA, and a clean inspection history if the line is headed for the clinic.
  • Capacity and lead time: ask for a realistic gene-to-RCB and gene-to-MCB timeline, current slot availability, and what a stability program adds, so the schedule fits your IND or first-in-human date.
  • Modality and indication fit: match the platform to your molecule (CHO or HEK293 for mAbs and complex proteins, microbial for peptides and enzymes, specialist hosts for viral vectors), and check they have run programs like yours.
  • Expression platform and IP terms: understand the licensing and royalty terms on the host or vector before signing, because some platforms carry downstream payments that follow the molecule for its commercial life.
  • Region and regulatory track record: weigh location against your filing geographies and any data-residency or supply-chain preferences, and ask how many of their lines have reached IND or BLA.
  • Data quality and transparency: insist on raw clone-screening data, stability results, and a clonality report you can drop into a regulatory filing, not just a summary slide.
  • IP and confidentiality: review ownership of the developed line, escrow or transfer rights if you change manufacturers, and confidentiality terms covering your sequence and process.

Frequently asked questions

How long does cell line development take?
For a standard CHO program, expect roughly three to six months from gene to a research cell bank with a selected clone and titer data. Adding a GMP master cell bank, working cell bank, and the genetic stability and adventitious agent testing needed for the clinic typically pushes the total past six months. Microbial strain development can be faster. Ask each CDMO for both the gene-to-RCB and gene-to-MCB timelines, since the banking and characterization stage is where schedules usually slip.
What is the difference between cell line development and strain development?
They are the same activity for different host types. Cell line development usually refers to mammalian systems like CHO and HEK293, used for antibodies, complex proteins, and viral vectors. Strain development refers to microbial hosts like E. coli and Pichia yeast, used for peptides, simpler proteins, and many enzymes. Buyers shop for both under one heading because the underlying decision is the same: build, characterize, and bank the production organism that expresses your molecule. The right host depends on your molecule's complexity and required post-translational modifications.
Why does clonality matter so much to regulators?
FDA and EMA expect assurance that your production line is derived from a single progenitor cell, because clonality underpins consistency and the comparability of every batch you make. Modern programs support the claim with single-cell cloning plus imaging evidence rather than statistics alone. A weak clonality story can surface as a deficiency during BLA review, which is an expensive place to discover it. When comparing CDMOs, ask exactly what clonality documentation they deliver and whether it has held up in prior filings.
Should I develop the cell line and manufacture drug substance at the same CDMO?
Keeping both under one roof removes a tech transfer and usually shortens the path to GMP material, which appeals when speed matters. Splitting them lets you pick the best specialist for each and keeps you from being locked to one manufacturer, but you absorb a tech transfer and the timeline and risk that come with it. Decide before you start: confirm the developing CDMO's line is genuinely portable, and check the contract for transfer and escrow rights so a future move is not held hostage.
Who owns the cell line and what are the licensing costs?
Two things to separate. You generally own the line built from your sequence, but the expression platform (the host and vector technology) is often licensed from the CDMO or a third party, and some platforms carry royalties or milestone fees that follow your molecule into commercial life. Read those terms before signing, because they can outweigh the upfront development fee over a product's lifetime. Confirm ownership, transfer rights, and any downstream payments in writing up front.
How does BioBridgeX work for sourcing a cell line development CDMO?
BioBridgeX is free for buyers and acts as the neutral marketplace. You tell us your molecule, host preference, and timeline, and we match you with qualified cell line and strain development CDMOs so you can compare them side by side. When you engage more than one supplier across your program, you compare quotes and contract directly with each, in one place, with a flat 2% success fee paid by the supplier, not by you. We cover all indications and modalities, so the same process works whether you need a microbial strain or a high-titer CHO line.

Source Cell Line / Strain Development with one contract

Compare transparent quotes from qualified Cell Line / Strain Development CDMOs, then contract once. Free for buyers.

Compare quotes